2023
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Kovacevich A, Weleff J, Claytor B, Barnett B. Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD. Journal Of Psychoactive Drugs 2023, 55: 672-679. PMID: 37650700, DOI: 10.1080/02791072.2023.2253538.Peer-Reviewed Original ResearchMeSH KeywordsAnosmiaChildCOVID-19FemaleHallucinogensHumansLysergic Acid DiethylamideMaleOlfaction DisordersPsilocybinConceptsLysergic acid diethylamidePsychedelic useOlfactory impairmentOlfactory improvementClassic psychedelic useCOVID-19-related anosmiaSerotonergic effectsIncreased neuroplasticityAnti-inflammatory effectsNaturalistic useAcid diethylamideOlfactory dysfunctionMicrosmiaPsilocybinRespiratory infectionsPsilocybin mushroomsTherapeutic benefitAnosmiaNovel treatmentReport improvementImpairmentPotential mechanismsBiological plausibilityGrowing bodyWomen
2021
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020
Barnett B, Parker S, Weleff J. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020. International Journal Of Drug Policy 2021, 99: 103473. PMID: 34624734, DOI: 10.1016/j.drugpo.2021.103473.Peer-Reviewed Original ResearchConceptsNational Institutes of HealthNational Institutes of Health grantsPsychedelic-assisted therapyResearch funding bodiesClinical trialsPublic funder of biomedical researchMental health conditionsNational Institutes of Health fundingNational Institutes of Health RePORTERFunding bodiesUnited States National Institutes of HealthSchedule 1 drugFunder of biomedical researchInstitutes of HealthFunding clinical trialsNIH grant supportHealth conditionsPsychedelic renaissanceUnited KingdomGrant fundingGrant databasesStudy periodPublic funders